Are there any medicines related to COVID-19 infections that are subject to public expense?

Currently, there are no new coronavirus infections that are subject to public expenditure.
Out-of-pocket expenses vary depending on the ratio of medical insurance that you have subscribed to (10% to 30%).

• Oral drugs
  Lagebrio, Pakylobid, Zocoba
• Infusion drugs
  Beklly
• Neutralizing antibodies
  Zebudi, ronaprib, evacheldo

  ---

※General distribution of "Zebuddy", "Lonaprib" and "Evashelld" have not been started, and only free transfer of purchased goods in Japan. (For nationally purchased products, there is no self-pay because medical fees are not calculated at medical institutions and pharmacies.)

Until the end of September 2023, the entire amount was paid by public expenses, and there was no self-pay.
In addition, from October 2023 to the end of March 2024, some self-pay was required.

[Reference] Out-of-pocket expenses for the treatment of COVID-19 infection (October 2023 to March 2024)

• medical expenses's out-of-pocket ratio: 3,000 yen
• medical expenses's out-of-pocket ratio of 20%: 6,000 yen
• medical expenses's out-of-pocket ratio of 30%: 9,000 yen

※Prescriptions, dispensing fees, etc. are not covered by public expenses, even if they are related to new coronavirus infection treatment.